Penn spinout Vetigenics, a clinical-stage startup focused on advancing antibody-based therapies for pets, announced that the first canine patient has received his first dose of Vetigenics’ fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.
“These therapies have the potential to transform the way veterinary oncologists treat cancer and the outcomes of their cancer patients. Vetigenics’ monoclonal antibodies offer new hope for families dealing with their pet’s diagnosis and treatment,” said Vetigenics co-founder Nicola Mason, BVetMed, PhD, DACVIM, MRCVS, as per PR Newswire.
Read more about Vetigenics and their clinical trials to treat cancer in pets here.